ACI today publicly rebuts the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
The Association for the Cannabinoid Industry (ACI) is the UK’s membership organisation for businesses committed to nurturing a safe, legal and flourishing commercial cannabis extract market.
Our vision is to create an innovative and ethical sector with the highest standards of product quality, consumer satisfaction and regulatory compliance.
We deliver vital stewardship for this emerging sector through constructive engagement with key stakeholders and thought leaders. Our team of scientific, regulatory and industry leaders provide expert support and guidance to our members.
Experts from the Association for the Cannabinoid Industry (ACI) and Centre for Medicinal Cannabis (CMC) have put together a detailed safety review paper of THC – Health Guidance Levels for THC in CBD products: Safety Assessment & Regulatory Recommendations. The paper recommends further research and makes policy recommendations.
ACI Forms Exclusive Partnership with PR Agency Ingredient Communications to Offer B2B Comms Support for Members
Today ACI announced an exclusive partnership with the UK’s leading PR agency specialising in B2B communications in the food and nutrition sectors, Ingredient Communications.
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.